Diabetic Peripheral Neuropathy R&D Pipeline Analysis Report, Q4 2020

October 2020
112 pages
ID: 5978169
Format: PDF
VPAResearch

Summary

Table of Contents

Diabetic Peripheral Neuropathy Pipeline Overview

The Q4 Diabetic Peripheral Neuropathy pipeline report is part of the VPA Metabolic Disorder disease pipeline service. This quarterly review describes the pipeline of drugs under development for Diabetic Peripheral Neuropathy, provides an update on the mechanism of action and targets, licensing and collaboration opportunities, company profiles including their business information, and market developments.

Diabetic Peripheral Neuropathy Disease Types, Symptoms, Causes, and Available Treatment Options
The comprehensive report on the indication presents Diabetic Peripheral Neuropathy disease overview, Diabetic Peripheral Neuropathy types, Diabetic Peripheral Neuropathy symptoms, causes, and FDA/EMA approved treatment options.

Diabetic Peripheral Neuropathy Pipeline Trends and Insights
The year 2020 witnessed progress in innovations and the number of pipeline agents researched for Diabetic Peripheral Neuropathy indication. The report presents near-term and long-term pipeline development trends and potential insights.

Diabetic Peripheral Neuropathy Company Trends and Insights
The report analyzes the development progress, current status, investments, partnerships, and other developments of 23 companies. Business profiles and contact details of the companies actively perusing Diabetic Peripheral Neuropathy pipeline are assessed.

Diabetic Peripheral Neuropathy R&D Pipeline Development Phase Trends and Insights
From the discovery stage of development to phase 3 development, all the potential pipeline drug candidates are analyzed in the report. Diabetic Peripheral Neuropathy discovery stage, research stage, Phase 1, phase 2, Phase 3, IND enabling studies are provided in the research.

Small Diabetic Peripheral Neuropathy companies look for licensing and collaboration partners
High R&D costs and long duration pose challenges for small companies operating in the industry. Further, the presence of large companies and stringent regulations act as barriers for Diabetic Peripheral Neuropathy pipeline development companies. Accordingly, a significant portion of small companies presents potential licensing and collaboration opportunities.

Diabetic Peripheral Neuropathy Pipeline Market News and Developments during 2020
The Diabetic Peripheral Neuropathy industry news, pipeline research, market developments including advancement in phases, pre-clinical study results, clinical trial launches, acquisitions and mergers, regulatory approvals, and others are included in the report.

Diabetic Peripheral Neuropathy Mechanism of Action and Targets
Leading Mechanism of Action and targets being researched by all the companies and their progress is included. New mechanisms of actions introduced during the year, route of administration, orphan drug designation, and others are provided in the study.

New molecular entity details
Drug candidates identified as new molecular entities by FDA, EMA, and other regulators are included in the research.

Sources and Research Methodology
Data is updated daily across diseases in the infectious pipeline service. We review our quarterly pipeline reports for the latest 5 years to present longitudinal insights.

Scope and Coverage
• Diabetic Peripheral Neuropathy pipeline development activities across the early phase, mid-stage, and late phase pipelines including therapeutic candidates
• Drug profiles comprising of drug overview, mechanism of action, co-developers, originators, route of administration, molecule type, orphan drug status, new molecular entity, area, and other details.
• Company-company partnerships, company-institute partnerships, and investment details of companies are included
• 23 companies are included including Achelios Therapeutics Inc, Applied Therapeutics Inc, Bionevia Pharmaceuticals, Bristol-Myers Squibb Co, Calchan Ltd, Celularity Inc, Commence Bio Inc, CSPC Pharmaceutical Group Ltd, Eli Lilly and Co, Exodos Life Sciences Limited, GNT Pharma Co Ltd, Grunenthal GmbH, Immune Pharmaceuticals In, Ion Channel Pharmacology LLC, Korea United Pharm Inc, Mitsubishi Tanabe Pharma Corp, Pfizer Inc, Praetego Inc, Reata Pharmaceuticals Inc, Seneca Biopharma Inc, Sonnet BioTherapeutics Holdings Inc, Sphaera Pharma Pte Ltd, Winsantor Inc,
• Disease overview, Pipeline trends, market analysis, and other developments
• Potential licensing/new business opportunities in Diabetic Peripheral Neuropathy pipeline market

Highlights
• Global coverage of companies and pipeline agents
• 2020 Trends, market analysis, and developments
• Potential growth opportunities
• Comprehensive details of drug candidates

Reasons to Buy
• Drive pipeline research and commercial assessment
• Assess most promising drug candidates and stay ahead of the competition
• Strengthen your pipeline through identifying business expansion and acquisition opportunities
• Develop new candidates based on most focused targets and mechanism of actions

Our reports have been used by over 10K customers, including:

Get Industry Insights. Simply.

Latest reports & slideshows with insights from top research analysts
150+ Million searchable statistics with tables, figures & datasets
More than 25,000 trusted sources

Single User License — provides access to the report by one individual.
Department License — allows you to share the report with up to 5 users
Site License — allows the report to be shared amongst all employees in a defined country
Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:

+1 718 618 4302
Contact by email

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ

How we can help
- I am not sure if the report I am interested in will fulfill my needs. Can you help me?
- Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
- We buy reports often - can ReportLinker get me any benefits?
- Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
- I have had negative experiences with market research reports before. How can you avoid this from happening again?
- We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.
Report Delivery
- How and when I will receive my Report?
- Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
Payment conditions
- What payment methods do you accept?
- 1. Credit card : VISA, American Express, Mastercard, or
  2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
  3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
- What are ReportLinker’s Payment Terms?
- All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
- Are Taxes and duties included?
- All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
- I’m not satisfied. Can I be refunded?
- No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
User license
- The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.

Purchase Reports From Reputable Market Research Publishers

Restless Legs Syndrome (Central Nervous System) - Drugs in Development, 2021

$ 2000
March 2021
57 pages

Restless Legs Syndrome (Central Nervous System) - Drugs in Development, 2021 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Restless Legs Syndrome - Drugs in Development, 2021, ...